Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 2/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.43 |
| ▸ | DCAF1 | Q9Y4B6 | 1/20 | 0.43 |
| ▸ | CAPN1 | P07384 | 7/20 | 0.42 |
| ▸ | CNR1 | P21554 | 2/20 | 0.41 |
| ▸ | CNR2 | P34972 | 2/20 | 0.41 |
| ▸ | CCR1 | P32246 | 2/20 | 0.40 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22886099 | 0.86 | CAPN1 (0.59) | CAPN1 | |
| SCHEMBL22897214 | 0.82 | DCAF1 (0.51) | PYGLDCAF1CNR1CNR2 | |
| SCHEMBL20027914 | 0.82 | DCAF1 (0.48) | PYGLADORA2ADCAF1CAPN1 | |
| SCHEMBL20028717 | 0.81 | DCAF1 (0.50) | PYGLDCAF1CNR1CNR2CCR1 | |
| SCHEMBL22885968 | 0.80 | DCAF1 (0.49) | PYGLADORA2ADCAF1CNR1CNR2 | |
| SCHEMBL20028410 | 0.79 | CAPN1 (0.59) | CAPN1 | |
| SCHEMBL22885969 | 0.79 | DCAF1 (0.48) | PYGLDCAF1 | |
| SCHEMBL20028150 | 0.78 | DCAF1 (0.41) | PYGLDCAF1CAPN1CNR1CNR2 | |
| SCHEMBL20027718 | 0.78 | DCAF1 (0.51) | PYGLDCAF1 | |
| SCHEMBL22897243 | 0.78 | DCAF1 (0.51) | PYGLDCAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210009564-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | BLADE THERAPERTICS INC (US) | 2021-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210009564-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | CAPNS1, CAPN9, CAPN1 | PYGL 719/4885ADORA2A 3846/4885DCAF1 2355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.